- Home
- USGO vs ZNTL Comparison
USGO vs ZNTL Comparison
Compare USGO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- ZNTL
- Stock Information
- Founded
- USGO 2015
- ZNTL 2014
- Country
- USGO United States
- ZNTL United States
- Employees
- USGO N/A
- ZNTL N/A
- Industry
- USGO Precious Metals
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- ZNTL Health Care
- Exchange
- USGO Nasdaq
- ZNTL Nasdaq
- Market Cap
- USGO 117.3M
- ZNTL 105.8M
- IPO Year
- USGO 2023
- ZNTL 2020
- Fundamental
- Price
- USGO $8.10
- ZNTL $1.99
- Analyst Decision
- USGO Strong Buy
- ZNTL Buy
- Analyst Count
- USGO 1
- ZNTL 7
- Target Price
- USGO $26.50
- ZNTL $8.46
- AVG Volume (30 Days)
- USGO 30.8K
- ZNTL 768.8K
- Earning Date
- USGO 08-13-2025
- ZNTL 08-06-2025
- Dividend Yield
- USGO N/A
- ZNTL N/A
- EPS Growth
- USGO N/A
- ZNTL N/A
- EPS
- USGO N/A
- ZNTL N/A
- Revenue
- USGO N/A
- ZNTL $26,865,000.00
- Revenue This Year
- USGO N/A
- ZNTL N/A
- Revenue Next Year
- USGO N/A
- ZNTL N/A
- P/E Ratio
- USGO N/A
- ZNTL N/A
- Revenue Growth
- USGO N/A
- ZNTL N/A
- 52 Week Low
- USGO $5.00
- ZNTL $1.01
- 52 Week High
- USGO $14.46
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- USGO 50.28
- ZNTL 78.59
- Support Level
- USGO $7.59
- ZNTL $1.55
- Resistance Level
- USGO $7.95
- ZNTL $1.70
- Average True Range (ATR)
- USGO 0.32
- ZNTL 0.12
- MACD
- USGO 0.05
- ZNTL 0.05
- Stochastic Oscillator
- USGO 63.62
- ZNTL 91.43
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.